The Herpes Simplex Virus 2 (HSV-2) is a chronic long-term condition that causes genital ulcers.  It is widely prevalent, with an estimated 13.2% or 491.5 million people aged 15-49 years worldwide living with HSV-2.

HSV-2 can lie dormant in nerve cells and become active again with periodic viral shedding episodes that cause unpleasant recurrent symptoms in some people as well as the risk of transmission to sexual partners.

Current treatment with antiviral medication is only partially effective in preventing recurrences and transmission to others. There is need for more potent, long-acting antiviral therapy.

Momentum Clinical Research are conducting a clinical study for a potential long-acting oral antiviral medication that aims to supress recurrent episodes of genital herpes.

You may be eligible to participate if you are 18 to 60 years old AND have recurrent episodes of genital herpes (HSV-2) and are otherwise in good health.

Study Duration:

For group 1 (HSV-2): x29 days of treatment and x12 clinic visits across 144 days.

Eligible participants will be compensated for travel-related costs.

The study is being conducted at the following locations:

• Momentum Darlinghurst

Please contact us on 1300 190 841 or info@momentumclinicalresearch.com.au for further information or follow the link below.